Research methods
Open-label extension studies
Why open-label extension data is useful but cannot establish long-term safety on its own.
Open-label extensions follow trial participants beyond the randomised period to characterise durability, late-onset adverse events and post-discontinuation trajectory.
What they can tell you
Durability of effect, late-onset safety signals not seen in shorter trials, and patterns of post-randomisation behaviour.
What they cannot tell you
Without an ongoing control group, open-label extensions cannot establish ongoing treatment effect at the precision of the original randomised period. Selection bias from who consents to extend is real.
Key takeaways
- OLEs are signal-rich but causally weaker than the original randomised period.
- Selection bias matters and should be interrogated.
What this primer does not provide
- Formal statistical training.
- Individual treatment, prescribing or dosing advice.
- Permission to skip the original publication of any trial cited.
Last reviewed 20 May 2026 · Open-label extension studies primer · Metabolic Peptides editorial team